title: Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects.
abstract: Multiregional clinical trials including Japanese subjects are playing a key role in new drug development in Japan. In addition to the consideration of differences in intrinsic and extrinsic ethnic factors, deciding the sample size of Japanese subjects is an important issue when a multiregional clinical trial is intended to be used for Japanese submission. Accumulated experience suggests that there are several points to consider, such as the basic principles described in the guidance document, drug development strategy, trial phase, and disease background. The difficulty of interpreting the results of Japanese trials should also be considered.
authors.affiliation: Biostatistics Group, Center for Product Evaluation, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. ando-yuki@pmda.go.jp
authors.forename: Yuki
authors.initials: Y
authors.lastname: Ando
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Uyama
mesh_terms: D004305:Dose-Response Relationship, Drug; D017277:Drug Approval; D005006:Ethnicity; D017408:Guidelines as Topic; D006801:Humans; D007564:Japan; D015337:Multicenter Studies as Topic / Q000379:methods / Q000706:statistics & numerical data*; D012107:Research Design / Q000706:statistics & numerical data*; D035842:Research Subjects; D018401:Sample Size